196 related articles for article (PubMed ID: 22319575)
1. Activation and inhibition of transglutaminase 2 in mice.
Dafik L; Albertelli M; Stamnaes J; Sollid LM; Khosla C
PLoS One; 2012; 7(2):e30642. PubMed ID: 22319575
[TBL] [Abstract][Full Text] [Related]
2. Role of transglutaminase 2 in celiac disease pathogenesis.
Klöck C; Diraimondo TR; Khosla C
Semin Immunopathol; 2012 Jul; 34(4):513-22. PubMed ID: 22437759
[TBL] [Abstract][Full Text] [Related]
3. Transglutaminase as a therapeutic target for celiac disease.
Sulic AM; Kurppa K; Rauhavirta T; Kaukinen K; Lindfors K
Expert Opin Ther Targets; 2015 Mar; 19(3):335-48. PubMed ID: 25410283
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
Chrobok NL; Bol JGJM; Jongenelen CA; Brevé JJP; El Alaoui S; Wilhelmus MMM; Drukarch B; van Dam AM
PLoS One; 2018; 13(4):e0196433. PubMed ID: 29689097
[TBL] [Abstract][Full Text] [Related]
5. Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury.
Siegel M; Strnad P; Watts RE; Choi K; Jabri B; Omary MB; Khosla C
PLoS One; 2008 Mar; 3(3):e1861. PubMed ID: 18365016
[TBL] [Abstract][Full Text] [Related]
6. Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study.
Rauhavirta T; Oittinen M; Kivistö R; Männistö PT; Garcia-Horsman JA; Wang Z; Griffin M; Mäki M; Kaukinen K; Lindfors K
J Clin Immunol; 2013 Jan; 33(1):134-42. PubMed ID: 22878839
[TBL] [Abstract][Full Text] [Related]
7. Thioredoxin-1 Selectively Activates Transglutaminase 2 in the Extracellular Matrix of the Small Intestine: IMPLICATIONS FOR CELIAC DISEASE.
Plugis NM; Palanski BA; Weng CH; Albertelli M; Khosla C
J Biol Chem; 2017 Feb; 292(5):2000-2008. PubMed ID: 28003361
[TBL] [Abstract][Full Text] [Related]
8. Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease.
Büchold C; Hils M; Gerlach U; Weber J; Pelzer C; Heil A; Aeschlimann D; Pasternack R
Cells; 2022 May; 11(10):. PubMed ID: 35626704
[TBL] [Abstract][Full Text] [Related]
9. An unprecedented dual antagonist and agonist of human Transglutaminase 2.
Yi MC; Palanski BA; Quintero SA; Plugis NM; Khosla C
Bioorg Med Chem Lett; 2015 Nov; 25(21):4922-4926. PubMed ID: 26004580
[TBL] [Abstract][Full Text] [Related]
10. Activation of extracellular transglutaminase 2 by thioredoxin.
Jin X; Stamnaes J; Klöck C; DiRaimondo TR; Sollid LM; Khosla C
J Biol Chem; 2011 Oct; 286(43):37866-73. PubMed ID: 21908620
[TBL] [Abstract][Full Text] [Related]
11. Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors.
Song M; Hwang H; Im CY; Kim SY
J Med Chem; 2017 Jan; 60(2):554-567. PubMed ID: 28122456
[TBL] [Abstract][Full Text] [Related]
12. Development of Potent and Selective Tissue Transglutaminase Inhibitors: Their Effect on TG2 Function and Application in Pathological Conditions.
Badarau E; Wang Z; Rathbone DL; Costanzi A; Thibault T; Murdoch CE; El Alaoui S; Bartkeviciute M; Griffin M
Chem Biol; 2015 Oct; 22(10):1347-61. PubMed ID: 26456735
[TBL] [Abstract][Full Text] [Related]
13. Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process.
Fleckenstein B; Molberg Ø; Qiao SW; Schmid DG; von der Mülbe F; Elgstøen K; Jung G; Sollid LM
J Biol Chem; 2002 Sep; 277(37):34109-16. PubMed ID: 12093810
[TBL] [Abstract][Full Text] [Related]
14. Substrates, inhibitors, and probes of mammalian transglutaminase 2.
Zhuang R; Khosla C
Anal Biochem; 2020 Feb; 591():113560. PubMed ID: 31874171
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase.
Hausch F; Halttunen T; Mäki M; Khosla C
Chem Biol; 2003 Mar; 10(3):225-31. PubMed ID: 12670536
[TBL] [Abstract][Full Text] [Related]
16. Elevated transglutaminase 2 activity is associated with hypoxia-induced experimental pulmonary hypertension in mice.
DiRaimondo TR; Klöck C; Warburton R; Herrera Z; Penumatsa K; Toksoz D; Hill N; Khosla C; Fanburg B
ACS Chem Biol; 2014 Jan; 9(1):266-75. PubMed ID: 24152195
[TBL] [Abstract][Full Text] [Related]
17. Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2.
Klöck C; Jin X; Choi K; Khosla C; Madrid PB; Spencer A; Raimundo BC; Boardman P; Lanza G; Griffin JH
Bioorg Med Chem Lett; 2011 May; 21(9):2692-6. PubMed ID: 21215619
[TBL] [Abstract][Full Text] [Related]
18. Transglutaminase 2 inhibitors and their therapeutic role in disease states.
Siegel M; Khosla C
Pharmacol Ther; 2007 Aug; 115(2):232-45. PubMed ID: 17582505
[TBL] [Abstract][Full Text] [Related]
19. Transglutaminase 2 in celiac disease: minireview article.
Caputo I; D'Amato A; Troncone R; Auricchio S; Esposito C
Amino Acids; 2004 Jul; 26(4):381-6. PubMed ID: 15290344
[TBL] [Abstract][Full Text] [Related]
20. Injection of prototypic celiac anti-transglutaminase 2 antibodies in mice does not cause enteropathy.
Lindstad CB; du Pré MF; Stamnaes J; Sollid LM
PLoS One; 2022; 17(4):e0266543. PubMed ID: 35385534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
